Advertisement

Neurologic Complications of Chronic Kidney Disease

  • Kavitha Vellanki
  • Vinod K. BansalEmail author
Neurology of Systemic Diseases (J Biller, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurology of Systemic Disease

Abstract

Chronic kidney disease (CKD) is an increasing problem worldwide and is now being recognized as a global health burden particularly for cardiovascular and cerebrovascular events. The incidence of stroke increases in the presence of CKD with a 3-fold increased rate reported in ESRD. Atrial fibrillation (AF) increases the risk of stroke in CKD. There is conflicting observational evidence regarding benefit of anticoagulation in CKD for prevention of stroke in AF as risk of bleeding is high. Overall, anticoagulant in CKD may be beneficial in appropriate patients with meticulous monitoring of international normalized ratio (INR). Neurological manifestations related to electrolyte disorders, drug toxicity, and uremia are common in CKD. Appropriate drug dosing, awareness of potential side effects of medications, prompt diagnosis, and treatment are essential in preventing long-term morbidity and mortality.

Keywords

Chronic kidney disease Stroke Atrial fibrillation Anticoagulation Cognitive impairment Uremia Drug toxicity 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Kavitha Vellanki and Vinod K. Bansal declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2013;3:1–150.CrossRefGoogle Scholar
  2. 2.
    Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimensions and perspectives. Lancet. 2013;382:260–72.PubMedCrossRefGoogle Scholar
  3. 3.•
    Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13:823–33. Review article discussing the cerebro-renal axis of neurological disorders.PubMedCrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention (CDC). National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014. http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm#1.
  5. 5.
    Toyoda K. Cerebrorenal interaction and stroke. Contrib Nephrol. 2013;179:1–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Ovbiagele B, Wing JJ, Menon RS, et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke. 2013;44:2409–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013;24:353–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ. 2010;341:c4249.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wang HH, Hung SY, Sung JM, Hung KY, Wang JD. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis. 2014;63:604–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Muntner P, Judd SE, McClellan W, et al. Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Nephrol Dial Transplant. 2012;27:166–73.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.••
    Masson P, Webster AC, Hong M, Turner R, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol. Dial. Transplant. First published online February 12, 2015. Meta-analysis and systematic review of studies assessing the risk of stroke in CKD. A total of 83 studies; 63 cohort (N = 2085225) and 20 randomized (N = 168516) trails reporting 30,392 strokes in total were assessed. A thorough review of all published data so far.Google Scholar
  13. 13.
    Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular and all-cause mortality: a pooled analysis of community based studies. JASN. 2004;15:1307–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159:1102–7.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.•
    Genovesi S, Rossi E, Gallieni M, Stella A, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015;30(3):491–8. Prospective observational study assessing mortality and bleeding risk in dialysis patients with atrial fibrillation receiving warfarin for anti-coagulation.PubMedCrossRefGoogle Scholar
  16. 16.••
    Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35. Retrospective cohort review of Danish national registries of all patients discharged from the hospital with diagnosis of atrial fibrillation. Warfarin decreased the risk of stroke in patients with non-end stage renal disease and also in patients who received renal replacement therapy.PubMedCrossRefGoogle Scholar
  17. 17.•
    Bondi AN, Lip GYH, Kamper AL, Hansen PR, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. JACC. 2014;64:2472–82. Retrospective cohort study assessing the risk of stroke in CKD by individual in CHA2DS2-VASc score and benefit of warfarin in each individual group.Google Scholar
  18. 18.
    Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? JAMA. 2014;311:913–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–33.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.•
    Shah M, Tsadok AM, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196–203. Population based retrospective study of dialysis patients with atrial fibrillation receiving warfarin involving Canadian population. Similar to Chan et al. from 2009, warfarin use did not show any benefit in stroke risk reduction but risk of bleeding was as high as 44%.PubMedCrossRefGoogle Scholar
  21. 21.
    Howard G, Cushman M, Howard VJ, Kissela BM, et al. Risk factors for intracerebral hemorrhage. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke. 2013;44:1282–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    El Husseini, Nada, et al. Chronic Kidney Disease and Stroke. Adv Chronic Kidney Dis, 21;(6):500–508Google Scholar
  23. 23.•
    Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke. 2013;44:2935–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens. 2010;28:1738–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc. 2012;1, e002097.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Nakagawa K, Hirai T, Takashima S, et al. Chronic kidney disease and CHADS (2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107:912–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts. Circulation. 2013;127:224–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Bautista J, Bellac A, Chaudhari A, Pekler G, et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J. 2015;0:1–6.Google Scholar
  30. 30.
    Reinecke H, Brand E, Mesters R, Schabitz WR, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. JASN. 2009;20(4):705–11.PubMedCrossRefGoogle Scholar
  31. 31.
    US Renal Data System. USRDS. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.Google Scholar
  32. 32.
    Sozio SM, Armstrong PA, Coresh J, Jaar BG, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. AJKD. 2009;54(3):468–77.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Krishna PR, Naresh S, Krishna GSR, Lakshmi AY, et al. Stroke in chronic kidney disease. Ind J Nephrol. 2009;19(1):5–7.CrossRefGoogle Scholar
  34. 34.
    Lee JG, Lee KB, Jang IM, et al. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc Dis. 2013;35:53–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Molshatzki N, Orion D, Tsabari R, et al. Chronic kidney disease in patients with acute intracerebral hemorrhage: association with large hematoma volume and poor outcome. Cerebrovasc Dis. 2011;31:271–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. J Neurol Sci. 2011;301:46–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study. Am J Kidney Dis. 2012;59:249–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke. 2009;40:1296–303.PubMedCrossRefGoogle Scholar
  39. 39.
    Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Lyrer PA, Fluri F, Gisler D, Papa S, et al. Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology. 2008;71:1548–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Naganuma M, Koga M, Shiokawa Y, et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis. 2011;31:123–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Gensicke H, Zinkstok AM, Roos YB, et al. IV thrombolysis and renal function. Neurology. 2013;81:1780–8.PubMedCrossRefGoogle Scholar
  43. 43.••
    Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311:919–28. Prospective observational multi-center cohort study from Swedish web based registry assessing 1 yr. mortality in patients with compromised renal function and atrial fibrillation who were receiving warfarin. Outcomes were pre-defined and all participants had a confirmed diagnosis of atrial fibrillation.PubMedCrossRefGoogle Scholar
  44. 44.
    Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.PubMedCrossRefGoogle Scholar
  45. 45.
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64(21):e1–76.PubMedCrossRefGoogle Scholar
  46. 46.
    Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.PubMedCrossRefGoogle Scholar
  47. 47.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Sarnak MJ, Tighiouart H, Scott TM, et al. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013;80:471–80.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. Neurology. 2006;67:216–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc. 2004;52:1863–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Drew DA, Weiner DE. Cognitive impairment in chronic kidney disease: keep vascular disease in mind. Kidney Int. 2014;85:505–7.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol. 2012;35(5):474–82.PubMedCrossRefGoogle Scholar
  53. 53.
    Kovesdy C, Lott E, Lu J, Malakauskas S, et al. Hyponatremia, hypernatremia and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125(5):677–84.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.•
    Sterns RH. Disorders of plasma sodium—causes, consequences, and correction. N Engl J Med. 2015;372:55–65. Review article exploring the etiology of sodium disorders and discussing the pathophysiology of neurological manifestations of overzealous correction.PubMedCrossRefGoogle Scholar
  55. 55.
    Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalemia. Br J Anaesth. 1993;70(2):226–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Siegel D, Hulley SB, Black DM, Cheitlin MD, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267(8):1083.PubMedCrossRefGoogle Scholar
  58. 58.
    Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol. 2010;25:2413–30.PubMedCrossRefGoogle Scholar
  59. 59.
    Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. CJASN. 2009;4(1):221–33.PubMedGoogle Scholar
  60. 60.
    Jha V. Commonly used renal drugs. In: Biller J, editor. Interface of neurology and internal medicine. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 211–6.Google Scholar
  61. 61.
    Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107(1):1–16.PubMedCrossRefGoogle Scholar
  62. 62.
    Heidland A, Sebekova K, Klassen A, Palkovits M. Mechanisms of acute uremic encephalopathy: early activation of Fos and Fra-2 gene products in different nuclei/areas of the rat brain. J Ren Nutr. 2010;20(5 Suppl):S44–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol. 2012;27:2205–11.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Medicine, Division of Nephrology and HypertensionLoyola University Medical CenterMaywoodUSA

Personalised recommendations